Potential confounders
| Drug | N | Mean age | Mean time from vaccine to antibody testing in days (range; SD) | N on prednisone (% of total on prednisone) | Mean prednisone dose in mg of those on prednisone | ||||||||
| Total | No adjust | Adjust | P value | No adjust | Adjust | P value | No adjust | Adjust | P value | No adjust | Adjust | P value | |
| Methotrexate (all) | 110 | 67 | 66 | 0.52 | 46 | 58 | 0.02 | 11 | 9 | 0.96 | 5.6 | 4.7 | 0.60 |
| (13) | (13) | (14–95; 23) | (19–113; 26) | (18) | (18) | ||||||||
| Methotrexate | 51 | 68 | 68 | 0.96 | 45 | 56 | 0.11 | 5 | 3 | 1.00 | 7 | 5 | 0.36 |
| (no biologic or JAK inhibitor) | (12) | (12) | (16–95; 23) | (20–104; 26) | (17) | (14) | |||||||
| JAK inhibitor | 23 | 58 | 60 | 0.95 | 41 | 34 | 0.32 | 0 | 1 | 0.48 | N/A | 7 | – |
| (16) | (14) | (14–83; 18) | (15–63; 15) | (8) | |||||||||
| Rituximab | 38 | 67 | 69 | 0.91 | 53 | 44 | 0.36 | 8 | 6 | 0.27 | 7.2 | 3.7 | 0.11 |
| (11) | (7) | (17–109; 26) | (17–86; 23) | (30) | (55) | ||||||||
| Abatacept | 27 | 68 | 64 | 0.64 | 56 | 48 | 0.70 | 2 | 4 | 1.00 | 5.5 | 4.4 | 0.32 |
| (13) | (17) | (26–96; 24) | (14–79; 22) | (18) | (25) | ||||||||
| Abatacept intravenous | 20 | 72 | 68 | 0.60 | 62 | 54 | 0.60 | 1 | 3 | 1.00 | 6 | 4.2 | 0.42 |
| (4) | (15) | (26–96; 27) | (14–79; 21) | (17) | (21) | ||||||||
| Abatacept subcutaneous | 7 | 62 | 41 | 0.22 | 48 | 27 | 0.28 | 1 | 1 | 1.00 | 5 | 5 | – |
| (14) | (18) | (32–86; 22) | (19–35; 11) | (20) | (50) | ||||||||